Extended data Fig. 2: Characterization of TKMG48-binding region of CD80.
From: PD-1 agonism by anti-CD80 inhibits T cell activation and alleviates autoimmunity
a, Recognition of the IgV-like domain of CD80 by TKMG48. Bindings of TKMG48 and 16-10A1 (another clone of anti-CD80 Ab) to DOdPL cells expressing indicated chimeric molecules of CD80 and CD86 are shown. b, Attenuation of TKMG48 binding to CD80 by the introduction of amino acid substitutions that abrogate cis-PD-L1-CD80 interactions. Bindings of TKMG48 and 16-10A1 to DOdPL cells expressing indicated CD80 mutants are shown. c, No competition between TKMG48 and 16-10A1 on CD80 binding. The bindings of TKMG48 and 16-10A1 to DOdPL cells pre-incubated with the indicated Abs (10 µg ml−1) are shown. Representative data of 3 independent experiments are shown.
